Ara Jo1, Lisa Scarton2, LaToya J O'Neal3, Samantha Larson1, Nancy Schafer4, Thomas J George5, Juan M Munoz Pena6. 1. Department of Health Services Research, Management and Policy, University of Florida, Gainesville, FL, USA. 2. Department of Family Community and Health Systems Science, College of Nursing, University of Florida, Gainesville, FL, USA. 3. Department of Family, Youth and Community Sciences, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, FL, USA. 4. Health Science Library, University of Florida, Gainesville, FL, USA. 5. Division of Hematology and Oncology, College of Medicine, University of Florida, Gainesville, FL, USA. 6. Division of Endocrinology, Diabetes, and Metabolism, College of Medicine, University of Florida, Gainesville, FL, USA.
Abstract
BACKGROUND: Despite improved survival rates, cancer survivors are experiencing worse health outcomes with complications of treatment, such as type 2 diabetes mellitus (T2D), that may deteriorate survivorship. The purpose of this review was to provide a comprehensive review of T2D incidence following cancer diagnosis. METHODS: The study included: (1) cohort studies, (2) cancer diagnosis by a doctor, (3) incidence of T2D after diagnosis of cancer, and (4) adult patients over 18 years. Studies that focused on patients who had T2D as a preexisting condition at cancer diagnosis were excluded. RESULTS: Of a total of 16 studies, overall incidence of T2D ranged from 5.4% to 55.3%. The highest T2D incidence rate was observed in colorectal patients with cancer (53%). While results in prostate patients with cancer were mixed, patients who underwent androgen deprivation therapy (ADT) had a significantly higher incidence of new-onset T2D (12.8%, p = 0.01). Patients treated with chemotherapy within 1-5 years of initial diagnosis of colorectal cancer were at approximately 30% higher risk of T2D. One study found that 48% of T2D was preventable with optimal management during the process of patient care. CONCLUSION: Blood glucose management may allow physicians to intervene early and improve outcomes among patients with cancer.
BACKGROUND: Despite improved survival rates, cancer survivors are experiencing worse health outcomes with complications of treatment, such as type 2 diabetes mellitus (T2D), that may deteriorate survivorship. The purpose of this review was to provide a comprehensive review of T2D incidence following cancer diagnosis. METHODS: The study included: (1) cohort studies, (2) cancer diagnosis by a doctor, (3) incidence of T2D after diagnosis of cancer, and (4) adult patients over 18 years. Studies that focused on patients who had T2D as a preexisting condition at cancer diagnosis were excluded. RESULTS: Of a total of 16 studies, overall incidence of T2D ranged from 5.4% to 55.3%. The highest T2D incidence rate was observed in colorectalpatients with cancer (53%). While results in prostate patients with cancer were mixed, patients who underwent androgen deprivation therapy (ADT) had a significantly higher incidence of new-onset T2D (12.8%, p = 0.01). Patients treated with chemotherapy within 1-5 years of initial diagnosis of colorectal cancer were at approximately 30% higher risk of T2D. One study found that 48% of T2D was preventable with optimal management during the process of patient care. CONCLUSION:Blood glucose management may allow physicians to intervene early and improve outcomes among patients with cancer.
Authors: Amresh D Hanchate; Kerri M Clough-Gorr; Arlene S Ash; Soe Soe Thwin; Rebecca A Silliman Journal: J Gen Intern Med Date: 2010-06-08 Impact factor: 5.128
Authors: D Harris; A Barts; J Connors; M Dahl; T Elliott; J Kong; T Keane; D Thompson; S Stafford; E Ur; S Sirrs Journal: Curr Oncol Date: 2013-12 Impact factor: 3.677